GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
According to Golden Ten Data, Rezera is a biotechnology company about to enter Phase III clinical trials, developing an oral NLRP3 inhibitor for inflammatory diseases. On Thursday, the company announced its IPO terms.
The Boston, Massachusetts-based company plans to raise $200 million by issuing 16.7 million shares in a price range of $11 to $13 per share. New investors and affiliates, including GSK (GSK.US), have expressed interest in subscribing to up to $25 million worth of shares in this IPO (accounting for 13% of the transaction). Based on the midpoint of the proposed range, Rezera’s fully diluted market capitalization will reach $254 million.
Rezera is developing oral NLRP3 inhibitors for cardiovascular and neuroinflammatory diseases. NLRP3 is an upstream driver of sterile inflammation. Its main drug candidate, ruvonoflast, has completed two Phase II trials in cardiometabolic diseases, and the company plans to initiate a Phase III trial for peripheral artery disease (PAD) in the first half of 2027, with results expected in 2028. The company is also developing trabzanoflast, a blood-brain barrier-penetrating NLRP3 inhibitor that has completed a Phase I trial for neuroinflammatory indications. The company retains global rights to all its drug candidates.
Founded in 2016, Rezera plans to list on Nasdaq under the ticker “RZRA”. Jefferies, TD Securities, and Cantor Fitzgerald will act as joint bookrunners for this transaction. Pricing is expected during the week of November 9, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Crypto prices
More
